reports
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG405...
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data Randomization to be Completed in Phase II Part in Q4 2025 2025 Half-Year Results and Business Update Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025) Transgene to report additional immunological data at a scientific conference in Q4 2025 Ongoing Phase II part with TG4050 in operable HNSCC Patient screening comp...
Données positives de la Phase I randomisée de TG4050, vaccin thérapeut...
Données positives de la Phase I randomisée de TG4050, vaccin thérapeutique individualisé néoantigénique contre le cancer – Fin de la randomisation de la partie Phase II au quatrième trimestre 2025 Résultats financiers du 1er semestre 2025 et point sur l’activité Données positives de Phase I évaluant TG4050 dans les cancers opérables de la tête et du cou1 100 % de survie sans récidive après deux ans de suivi des patients – Données communiquées lors d’une présentation orale à l’ASCO (juin 2025)Présentation de nouvelles données d’immunologie lors d’une conférence scientifique au quatrième t...
Availability of Transgene’s Half-Year Financial Report as of June 30, ...
Availability of Transgene’s Half-Year Financial Report as of June 30, 2025 TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025. The document is available on the Company’s website: , in the “Investors/Financial information” section. This report comprises the following documents: 2025 half-year financial statements;Half-year management report;Statutory Auditors’ report on the 2025 half-year financial statements;Declaration by the person responsible for this hal...
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025 TRANSGENE (Paris : TNG) annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers le rapport semestriel au 30 juin 2025. Il peut être consulté sur le site internet de la société à l’adresse suivante : , dans la rubrique « Investisseurs – Informations financières ». Le rapport semestriel comprend les documents suivants : Information financière semestrielle 2025 ;Rapport semestriel d’activité ;Rapport des commissaires aux comptes sur l’information financière semestrielle 2025 ;Attes...
Autolus Therapeutics to Present Clinical Data Update at the American C...
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025 LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated f...
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
ALDEL DELFINGEN INDUSTRY SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
GBT GUERBET SA
GOE GROUPE GORGE SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
GNFT GENFIT SA
SESL SES-IMAGOTAG SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
FLU FLUGHAFEN WIEN AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
UPG UNIFIEDPOST GROUP
ECMPA EUROCOMMERCIAL PROPERTIES NV
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
ALDEL DELFINGEN INDUSTRY SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
GBT GUERBET SA
GOE GROUPE GORGE SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
GNFT GENFIT SA
SESL SES-IMAGOTAG SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
FLU FLUGHAFEN WIEN AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
UPG UNIFIEDPOST GROUP
ECMPA EUROCOMMERCIAL PROPERTIES NV
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Team Pharma
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Team Pharma
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studi...
Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen Stadium (extensive-stage small cell lung cancer, „ES-SCLC“) und untermauern das Potenzial von Pumita...
First Disclosure of Global Interim Phase 2 Data for BioNTech and Brist...
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed object...
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September. Cantor Global Healthcare Conference Fireside Chat: Friday, September 5, 2025, at 8...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults...
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the country NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — (NYSE: PFE, “Pfizer”) and (Nasdaq: BNTX, “BioNTech”) ...
Adaptimmune Therapeutics Plc: 1 director
A director at Adaptimmune Therapeutics Plc sold 3,250,000 shares at 0.071USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
- Jacob Mekhael
Autolus 2Q25 confirms the strong Aucatzyl US launch, EU launch put on ...
Yesterday before US market open, Autolus reported 2Q25 Aucatzyl sales of $20.9m, coming in above expectations (CSS: $13.4m). 1H25 sales of $29.9m implies 66 infused patients (i.e. approx. 6% market share), and points to a stronger than anticipated launch, which means our KBCS FY25 sales estimate of $43m is looking on the low end. Despite the strong US performance, the stock took a hit, likely due to the EU launch being put on hold, though we think this could protect the US business from an MFN p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.